NexCourse® Colorectal Cancer

Choose the right colorectal cancer treatment with confidence

Problem Statement

Each year, over 140,000 people in the U.S. are diagnosed with colorectal cancer.1
Colorectal Cancer is Widespread and Rising

Colorectal cancers often develop without symptoms, and many cases metastasize before diagnosis. Quick, decisive treatment can increase your patient’s long-term outcome.

A Range of Treatments

With a number of targeted therapies available, understanding your patient’s molecular profile is essential to prescribing potentially effective treatment.

Clinical Need

Colorectal cancer requires comprehensive testing that leverages important biomarkers and determines the best course of action
Identifying Key Mutations

Without molecular testing for therapeutically important genes, you may not know which treatments are potentially more effective for your colorectal cancer patients. You need a powerful, comprehensive test that offers relevant prognostic and predictive information.

Enter NexCourse Colorectal

NexCourse Colorectal provides you with actionable results for your patients with colorectal cancer

How it works

NexCourse Colorectal is a suite of powerful molecular tests
Tissue Collection

We start with a formalin fixed, paraffin-embedded (FFPE) tissue and test each sample for relevant biomarker expression.

Molecular Testing

Using advanced molecular testing, NexCourse Colorectal analyzes your patient’s relevant biomarkers, including KRAS, BRAF, and Microsatellite Instability (MSI).

Targeted Therapies

NexCourse Colorectal makes it easy to prescribe the right targeted therapy
EGFR Inhibitors

NexCourse Colorectal accurately analyzes KRAS for mutations, which indicates your patient’s likelihood of response to EGFR inhibitors. Patients with positive KRAS results are less likely to respond to EGFR inhibitors.2-3 Patients with a positive BRAF mutation have an unfavorable prognosis regardless of treatment.4

Microsatellite Instability (MSI)

Approximately 15% of colorectal cancers display MSI, which is the result of loss of DNA mismatch repair activity. Patients who demonstrate high-level microsatellite instability (MSI-H) have improved survival and receive no benefit from fluorouracil (FU)-based adjuvant therapy.5-6 MSI may also be associated with inherited Lynch Syndrome.7

The NexCourse Colorectal Advantage

A comprehensive test for a confident course of treatment
A Clear Direction

NexCourse Colorectal helps you determine which treatment is best for your colorectal cancer patient. We support NexCourse Colorectal actionable results with a patient-specific summary report and clinically relevant information, so you can manage your patient’s treatment with confidence. NexCourse Colorectal allows you to identify crucial biomarkers that predict therapy response and prognosis—so you can choose the most appropriate treatment.


  1. Howlader N, et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD,, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
  2. Lièvre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-9.
  3. Amado RG, et al. Wild-type (WT) KRAS is required for panitumumab efficacy in patient-with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-34.
  4. Di Nicolantonio F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705-12.
  5. Popat S, et al. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609-18.
  6. Des Guetz G, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer.2009;45(10):1890-6.
  7. Boland CR and Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073-2087.